Ginkgo Bioworks Holdings (DNA) Cash from Investing Activities (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Cash from Investing Activities for 7 consecutive years, with $11.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Investing Activities rose 117.35% year-over-year to $11.1 million; the trailing twelve-month figure through Jun 2026 stood at $56.5 million (up 119.77% YoY), and the FY2025 full-year result was -$240.3 million, down 286.09% from the prior year.
• Cash from Investing Activities retreated to $11.1 million in Q2 2026 per DNA's latest filing, from $23.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $95.1 million in Q4 2025 and bottomed at -$198.7 million in Q1 2025.
• Historically, Cash from Investing Activities has averaged -$23.1 million across 5 years, with a median of -$13.9 million in 2022.
• The widest YoY moves for Cash from Investing Activities: up 826.78% in 2025, down 1540.66% in 2025.
• Over 5 years, Cash from Investing Activities stood at $29.7 million in 2022, then sank by 256.94% to -$46.7 million in 2023, then jumped by 71.97% to -$13.1 million in 2024, then jumped by 826.78% to $95.1 million in 2025, then tumbled by 88.34% to $11.1 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $11.1 million, $23.1 million, and $95.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.